Skip to main content
. 2022 Nov 15;12(11):e065299. doi: 10.1136/bmjopen-2022-065299

Table 2.

Results of base case analysis

Treatment Cost ($) LYs QALYs ICER ($/LY) ICER ($/QALY)
Lap+Cap 54 399.1 2.136 1.569
Ner+Cap 58 698.3 2.567 1.908 9970.1 12 670.2

Cap, capecitabine; ICER, incremental cost-effectiveness ratio; Lap, lapatinib; LY, life-year; Ner, Neratinib; QALY, quality-adjusted life year.